Lindsey Eichinger
Ariadne Diagnostics (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, Lung Cancer Research Studies, Cancer Mechanisms and Therapy, Epigenetics and DNA Methylation
Most-Cited Works
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → DNA repair is indispensable for survival after acute inflammation(2012)76 cited
- → Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models(2015)10 cited
- → Aag DNA Glycosylase Promotes Alkylation-Induced Tissue Damage Mediated by Parp1(2013)4 cited
- → Abstract 807: Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models(2018)1 cited
- → Data from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2023)
- → Abstract 2924: Aberrant SWI/SNF complexes lacking SMARCA2 or SMARCA4 differentially affect cell state and response to a novel SMARCA2/4 inhibitor(2020)
- → Abstract 1768: Identification of a potent, orally-available SMARCA2/4 inhibitor with in vitro and in vivo activity in preclinical models of SMARCA4-mutant NSCLC(2020)
- → Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2023)